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Abstract
Background: Bacterial pneumonia is still a substantial cause of morbidity and mortality in HIV-infected patients in the era of
combination Antiretroviral Therapy. The benefit of tobacco withdrawal on the risk of bacterial pneumonia has not been
quantified in such populations, exposed to other important risk factors such as HIV-related immunodeficiency. Our objective
was to estimate the effect of tobacco smoking withdrawal on the risk of bacterial pneumonia among HIV-infected
individuals.
Methodology/Principal Findings: Patients of the ANRS CO3 Aquitaine Cohort with $ two visits during 2000–2007 and
without bacterial pneumonia at the first visit were included. Former smokers were patients who stopped smoking since $
one year. We used Cox proportional hazards models adjusted on CD4+ lymphocytes (CD4), gender, age, HIV transmission
category, antiretroviral therapy, cotrimoxazole prophylaxis, statin treatment, viral load and previous AIDS diagnosis. 135
cases of bacterial pneumonia were reported in 3336 patients, yielding an incidence of 12 % patient-years. The adjusted
hazard of bacterial pneumonia was lower in former smokers (Hazard Ratio (HR): 0.48; P=0.02) and never smokers (HR: 0.50;
P=0.01) compared to current smokers. It was higher in patients with ,200 CD4 cells/mL and in those with 200 to 349 CD4
cells/mL (HR: 2.98 and 1.98, respectively; both P,0.01), but not in those with 350 to 499 CD4 cells/mL (HR: 0.93; P=0.79),
compared to those with $500 CD4 cells/mL. The interaction between CD4 cell count and tobacco smoking status was not
statistically significant.
Conclusions/Significance: Smoking cessation dramatically reduces the risk of bacterial pneumonia, whatever the level of
immunodeficiency. Smoking cessation interventions should become a key element of the clinical management of HIV-
infected individuals.
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Introduction
Bacterial pneumonia is still a substantial cause of morbidity and
mortality in HIV-infected patients in the era of combination
Antiretroviral Therapy (cART). Indeed, around 10% of the causes
of severe morbidity and 5% of the causes of death are related to a
bacterial pneumonia in industrialized countries [1,2]. In the
general population, tobacco smoking is well-known as a major
modifiable risk factor of respiratory tract infections [3]. Pulmonary
infections in tobacco smokers are mediated by local inflammatory
modifications and a significant depression in the percentage and
absolute numbers of CD4+ and CD8+ lymphocytes [4]. Among
HIV-infected patients, the prevalence of tobacco smoking is very
high, generally reported around 50% in European HIV cohorts
[5,6], compared to 27% in the general population of comparable
age and gender [7]. Recent studies have confirmed the effect of
tobacco smoking on respiratory tract infections in HIV-infected
patients [8,9,10], and promoted tobacco smoking withdrawal as a
priority. However, the benefit of tobacco withdrawal on the risk of
bacterial pneumonia has not been quantified in such populations,
exposed to other important risk factors such as HIV-related
immunodeficiency [11]. In addition, respiratory tract immuno-
logical modifications due to HIV infection might interact with the
effect of tobacco smoking [12,13,14].
This study aimed at estimating the effect of tobacco smoking
withdrawal on the risk of bacterial pneumonia among HIV-
infected individuals in the era of cART, and its variation according
to the level of immunodeficiency.
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Ethics Statement
The ANRS CO3 Aquitaine cohort was granted ethics
permission from the institutional review board of the ANRS
(Agence nationale de recherched sur le sida et les he ´patites virales).
All patients included in the ANRS CO3 Aquitaine Cohort have
signed an informed consent.
Study Sample
All patients of the ANRS CO3 Aquitaine Cohort with at least
two visits during the 2000–2007 period, free of bacterial
pneumonia at first visit and with available data on tobacco
consumption were included in the study. The ANRS CO3
Aquitaine Cohort enrols all HIV-infected in- or outpatients of the
participating clinic wards of the Bordeaux University Hospital
and five other public hospitals in Aquitaine, south-western
France, since 1985 [15]. Tobacco smoking status is recorded at
inclusion (history of tobacco smoking and current status) and at
each visit (current status only) with clinical, biological and
therapeutic data.
Outcome Measures
Specific radiological signs including alveoli consolidation
limited or not to a segment or lobe or diffuse bilateral reticulo-
nodular pattern were a pre-requesite to define cases of bacterial
pneumonia. Cases of pneumonia excluded tuberculosis and
other mycobacteria. Bacterial pneumonia considered for this
analysis were classified into two categories: (1) ‘‘confirmed’’
(clinical and specific radiological signs together with a bacteri-
ological confirmation) or (2) ‘‘probable’’ (clinical and specific
radiological signs together with a successful antibacterial
treatment). Smoking status was defined as current smokers,
never smokers and former smokers (i.e.: patients who had
stopped smoking since at least one year) at each follow-up visit.
Four categories of immunological status were defined based on
CD4 count: ,200 cells/mL, 200 to 349 cells/mL, 350 to
499 cells/mLa n d$500 cells/mL.
Statistical Analysis
Time to a first episode of bacterial pneumonia was calculated
as the difference between the date of the first visit in the 2000–
2007 period and the date of diagnosis of bacterial pneumonia or
the date of the last visit within the study. Tobacco smoking status
was taken into account as a time-dependent variable as cessation
attempts and relapses are frequent in HIV-infected populations
(Encrenaz G et al. Curr HIV Res. 2009. In press). Explanatory
variables included gender, age at first visit, HIV infection
through intravenous drug use [IDU] and, as time-dependent
variables, CD4 cell count, previous diagnosis of AIDS, plasma
HIV RNA, cART (defined as a combination of at least three
antiretrovirals), cotrimoxazole prophylaxis and statin treatment.
Indeed, this latter variable has been reported as a protective
factor in recent studies in patients with chronic conditions
[16,17]. Latest values were considered for time-dependent
variables.
We estimated the incidence rate of bacterial pneumonia per
1000 patient-years with its corresponding 95% confidence interval
(CI), assuming that time-dependent variables were constant
between each measurement. Cox proportional hazards models
including a term of interaction between CD4 cell count and
tobacco smoking status were used. Statistical analyses were
performed using SAS (version 9.1; SAS Institute, Cary, NC).
Results
Out of 4365 patients enrolled in the ANRS CO3 Aquitaine
Cohort seen at least once in 2000–2007, 3336 (76%) were
included in this study. Eight hundred and fifty five (20%) patients
had no data available on tobacco smoking status, 30 (1%)
presented a bacterial pneumonia at the first visit and 144 (3%)
had only one visit during the 2000–2007 period. The 1029
excluded patients did not differ significantly from the 3336
patients available for the analysis in terms of age (40 years old on
average in both groups), HIV transmission categories (injecting
drug users: 20% versus 21%; heterosexual: 36% versus 30%),
proportion of cART-treated patients (64% versus 67%), plasma
HIV RNA (54% versus 50% with $1000 copies/ml), mean CD4
count (449 versus 450 cells/mL) and proportion of patients with a
previous AIDS diagnosis (21% in both groups). Excluded patients
were less frequently male (68% as compared to 74% in the study
sample, P,0.001). Baseline characteristics of the 3336 included
patients are shown in table 1.
Among the 1779 (53%) current smokers at inclusion, 277
(16%) stopped smoking for at least 1 year during follow-up and
were considered former smokers. Among the 411 (12%) former
smokers at inclusion, 164 (40%) relapsed during follow-up.
Among the 1146 (34%) never smokers at inclusion, 41 (4%) did
start smoking during follow-up. During a median follow-up of
3.3 years (inter-quartile range [IQR]: 1.6–5.1) and a median
number of 12 visits (IQR: 6–21), 135 first episodes of bacterial
pneumonia were reported. Of these, 51 (38%) required an
hospitalization. Of the 104 episodes of bacterial pneumonia
diagnosed in tobacco smokers, 38 (37%) required an hospital-
ization as compared to 50% in former and never smokers.
Overall, 104 (77%) of the bacterial pneumonia events were
classified as probable. Of the 31 (23%) with documented bacteria
(confirmed cases), Streptococcus pneumoniae (22 cases) was the most
common. Other identified organisms were Pseudomonas (6 cases),
Staphylococcus aureus (2 cases) and Haemophilus influenzae (1 case).
Seventy eight (58%) pneumonia episodes were diagnosed between
November and April, i.e influenza virus epidemics period.
The overall incidence of bacterial pneumonia was 12.0 per
1000 patient-years (CI: 9.9–14.0). It was 15.9 per 1000 patient-
years (CI: 13.1–19.3) when patients were smoking, 7.9 per 1000
patient-years (CI: 4.2–14.9) in former smokers and 5.9 per 1000
patient-years (CI: 3.5–10.0) in never smokers. The incidence of
bacterial pneumonia was 28.8 (CI: 16.7–49.8) and 16.5 (CI: 9.5–
28.4) per 1000 patient-years among patients with ,200 and
those with 200 to 349 CD4 cells/mL, respectively. It was 7.7 per
1000 patient-years among patients with $350 CD4 cells/mL
(table 2).
In the multivariate analysis, the interaction between CD4 count
and tobacco smoking status was not significant (P=0.44 and 0.34
for the relation between current smokers and former and never
smokers, respectively). The adjusted hazard of bacterial pneumo-
nia was significantly lower in former smokers compared to current
smokers (Hazard Ratio (HR): 0.48; CI: 0.26–0.90; P=0.02). It was
also significantly lower in never smokers compared to current
smokers (HR: 0.50; CI: 0.29–0.86; P=0.01). The hazard of
bacterial pneumonia was higher when CD4 count was
,200 cells/mL (HR: 2.98; CI: 1.80–4.94; P,0.001) or between
200 and 349/mm
3 (HR: 1.98; CI: 1.25–3.15; P=0.004) as
compared when CD4 count $500 cells/mL. The hazard of
bacterial pneumonia did not differ between patients with CD4
count between 350 and 499 cells/mL and those with CD4 count
$500 cells/mL (HR: 0.93; CI: 0.54–1.60; P=0.79). In this final
model, the hazard of bacterial pneumonia was also higher among
HIV, Tobacco and Pneumonia
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,1000 copies/ml) (HR: 1.75; CI: 1.19–2.56; P=0.004), among
IDUs versus others (HR: 1.87; CI: 1.27–2.73; P=0.001), among
women versus men (HR: 1.56; CI: 1.07–2.27; P=0.02) and
among patients aged between 50 and 60 years (HR: 3.53; CI:
1.13–10.98; P=0.03) and those aged $60 years (HR: 8.30; CI:
2.37–29.04; P,0.001) compared to those aged ,30 years (table 2).
Discussion
Bacterial pneumonia is a major cause of morbidity in HIV-
infected patients in the cART era. In our study, the incidence of
bacterial pneumonia was 12 per 1000 patient-years, comparing
with results reported in previous studies (8 to 20 per 1000 patient-
years) [1,9,10].
Table 1. Baseline characteristics of patients included in the analysis.
Category Sub-category N Median Interquartile Range n %
95% confidence
interval
Tobacco smoking status 3336
Current smokers 1779 53.3 [51.6–55.0]
Former smokers 411 12.3 [11.2–13.4]
Never smokers 1146 34.3 [32.7–36.0]
CD4+ lymphocyte count (cells/mL) 3334 421.0 [254.0–603.0]
$500 1238 37.1 [35.5–38.8]
[350–499] 757 22.7 [21.3–24.2]
200–349 742 22.3 [20.8–23.7]
,200 597 17.9 [16.6–19.2]
Gender 3336
Men 2480 74.3 [72.9–75.8]
Women 856 25.7 [24.2–27.1]
Age (years) 3336 39.6 [34.5–46.0]
,30 349 10.5 [9.4–11.5]
[30–40] 1306 39.2 [37.5–40.8]
[40–50] 1122 33.6 [32.0–35.3]
[50–60] 397 11.9 [10.8–13.1]
$60 162 4.9 [4.2–5.6]
Plasma HIV RNA (copies/ml) 3303
$1000 1643 49.7 [48.0–51.5]
,1000 1660 50.3 [48.5–52.0]
HIV transmission categories 3336
Heterosexual 1015 30.4 [28.9–32.0]
Homo- and bisexual 1305 39.1 [37.5–40.8]
Injecting drug users 707 21.2 [19.8–22.6]
Other 309 9.3 [8.3–10.3]
CDC stage 3336
A 1909 57.2 [55.6–58.9]
B 728 21.8 [20.4–23.2]
C 699 20.9 [19.6–22.3]
cART 3336
Yes 2231 66.9 [65.3–68.5]
No 1105 33.1 [31.5–34.7]
Cotrimoxazole prophylaxis 3336
Yes 64 1.9 [1.4–2.4]
No 3272 98.1 [97.6–98.6]
Statin treatment 3336
Yes 67 2.0 [1.6–2.5]
No 3269 98.0 [97.5–98.4]
cART: combination Antiretroviral Therapy.
ANRS CO3 Aquitaine Cohort, 2000–2007.
doi:10.1371/journal.pone.0008896.t001
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bacterial pneumonia: non modifiable risks factors such as age,
infection through IDU and gender; HIV infection; and tobacco
smoking.
As previously reported, patients infected through IDU had a
higher risk of bacterial pneumonia than other patients [10,18].
This might be explained by a poorer antiretroviral therapy
adherence in these patients [19]. Furthermore, daily cannabis
consumption, a frequent practice in this category of patient
[20,21], may contribute to this high rate of bacterial pneumonia
[22].
HIV-infected women presented a higher risk of bacterial
pneumonia than men. This result was observed after adjusting
for the main risk factor for bacterial pneumonia. However, we did
not adjust our analysis for precarious socio-economic conditions
and delayed access to care which are more prevalent in women
Table 2. Factors associated with the hazard of bacterial pneumonia among HIV-infected patients in the era of cART.
Category Sub-category
Univariate analysis (3336 patients/135 events)
Incidence rates (% patients-years)
Multivariate analysis 3303
patients/135 events
N events Patients-years Incidence 95% CI
Hazard
Ratio 95% CI P
Tobacco smoking status
Current smokers 104 6546 15.9 [13.1–19.3] 1
Former smokers 12 1513 7.9 [4.2–14.9] 0.48 [0.26–0.90] 0.02
Never smokers 19 3228 5.9 [3.5–10.0] 0.50 [0.29–0.86] 0.01
CD4+ lymphocyte count (cells/mL)
$500 39 4941 7.9 [5.8–10.8] 1
[350–499] 20 2717 7.4 [3.9–13.7] 0.93 [0.54–1.60] 0.79
200–349 38 2309 16.5 [9.5–28.4] 1.98 [1.25–3.15] 0.004
,200 38 1317 28.8 [16.7–49.8] 2.98 [1.80–4.94] ,0.001
Gender
Men 92 8433 10.9 [6.8–17.4] 1
Women 43 2853 15.1 [11.2–20.3] 1.56 [1.07–2.27] 0.02
Age (years)
,30 4 1084 3.7 [1.4–09.8] 1
[30–40] 64 4697 13.6 [3.3–55.7] 2.38 [0.86–6.62] 0.10
[40–50] 47 3747 12.5 [3.0–51.6] 2.70 [0.96–7.61] 0.06
[50–60] 13 1294 10.0 [2.3–44.5] 3.53 [1.13–10.98] 0.03
$60 7 464 15.1 [3.1–72.7] 8.30 [2.37–29.04] ,0.001
Plasma HIV RNA (copies/ml) *
,1000 72 7557 9.5 [7.1–11.1] 1
$1000 63 3729 16.9 [11.2–25.4] 1.75 [1.19–2.56] 0.004
HIV transmission categories
Other 78 8778 8.9 [7.2–11.2] 1
Injecting drug users 57 2508 22.7 [15.1–34.1] 1.87 [1.27–2.73] 0.001
Previous diagnosis of AIDS *
No 90 8751 10.3 [8.4–12.6] 1
Yes 45 2535 17.8 [11.7–26.8] 1.20 [0.82–1.77] 0.35
cART *
No 30 2553 11.8 [8.2–16.8] 1
Yes 105 8733 12.0 [7.0–20.7] 0.89 [0.57–1.39] 0.60
Cotrimoxazole prophylaxis *
No 133 11141 11.9 [10.1–14.1] 1
Yes 2 145 13.8 [3.4–56.2] 0.76 [0.18–3.18] 0.71
Statin treatment *
No 131 10768 12.2 [10.3–14.4] 1
Yes 4 518 7.7 [2.8–21.2] 0.56 [0.20–1.54] 0.26
*Time-updated variables.
cART: combination Antiretroviral Therapy.
CI: Confidence Interval.
ANRS CO3 Aquitaine Cohort, 2000–2007.
doi:10.1371/journal.pone.0008896.t002
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[23,24]. We cannot exclude a higher susceptibility to bacterial
pneumonia in HIV-infected women but further research is needed
to explore this hypothesis.
We showed that HIV infection increases the risk of bacterial
pneumonia through the virus itself and through the related
immunodeficiency. As recognized in earlier cohort studies [9,10],
we observed that the risk of bacterial pneumonia was higher in
patients with plasma HIV RNA above 1000 copies/ml. One
hypothesis is that HIV infection is associated with defects in
humoral immunity in the lung, leading to an increase susceptibility
to infections [25]. Immunodeficiency is generally reported as the
major risk factor of bacterial pneumonia in HIV-infected
individuals [1,18,26,27]. In our study, the incidence of bacterial
pneumonia dramatically increased in patients with a CD4 count
,350 cells/mL compared to those with a CD4 count above this
threshold. This emphasizes the need for early HIV diagnosis and
initiation of antiretroviral therapy at high levels of CD4 count, in
order to preserve cellular immunity [28,29].
But there are other ways of preventing bacterial pneumonia in
HIV-infected patients. Recent studies have reported that pneu-
mococcal vaccination was effective in HIV-infected patients
[30,31]. In our study, the most commonly reported bacterium
was Streptococcus pneumonia. We did not have any data on the
proportion of patients who received a pneumococcal vaccine but
these results should emphasize its use in HIV-infected patients. We
also reported that 59% of bacterial pneumonia episodes were
diagnosed during the period of influenza virus epidemics which is
a risk factor for respiratory tract infections [32]. The use of
influenza vaccination would also be an important option especially
in the context of pandemic situation although data are lacking on
its clinical efficacy and safety in HIV-infected patients [33].
Finally, our paper adds original information for the prevention
of bacterial pneumonia in HIV-infected patients. Firstly, for the
first time in such populations, we showed that after at least one
year of tobacco smoking abstinence, the risk of bacterial
pneumonia is significantly reduced and compares to the risk
observed in never smokers. Secondly, as noted by the absence of
interaction between tobacco smoking status and HIV induced
immunodeficiency, tobacco smoking cessation is effective in
preventing bacterial pneumonia whatever the level of immunode-
ficiency. These are evidences for promoting tobacco smoking
cessation in HIV infected patients. However, we showed that a
high proportion of former smokers relapsed during follow-up, even
after at least one year of abstinence. This reinforces the need for
specific tobacco cessation interventions in such populations to
lower the burden of bacterial pneumonia and, more generally, all
tobacco-related morbidities.
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